FDA OTC Head Ganley Talks Third Class, Plan B And Drug Switches
This spring, FDA's Division of OTC Drug Products will be elevated to full office status within the Center for Drug Evaluation & Research. OTC Division Director Charles Ganley, MD, sat down with "The Tan Sheet" on Dec. 17 to discuss the ramifications of the organizational change, as well as hot-button issues such as the current Rx-to-OTC switch environment, possible monograph system improvements and advisory committee reviews.
More from Archive
More from Pink Sheet
Europe’s vaccines industry wants to make sure immunizations “are not forgotten” by policymakers who are overseeing the EU Health Technology Assessment Regulation. It has highlighted several nuances of vaccines that should be addressed over the coming years.
A new chapter that will be published in the European Pharmacopoeia soon is expected to provide a comprehensive framework for the production and quality control of cell-based preparations. Meanwhile, an existing chapter has been revised to facilitate the implementation of rapid microbiological testing methods.
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.